An Early Phase 1 Study of Asciminib With or Without Sildenafil for Brain Tumors
Washington University School of Medicine
Summary
Dissemination of medulloblastoma is an independent risk factor of poor prognosis. Dissemination of medulloblastoma at recurrence is nearly universally fatal. ABL1 and 2 have been recently found to mediate the dissemination of medulloblastoma. Genetically inactivating ABL1 and 2 resulted in decreased leptomeningeal medulloblastoma and improved overall survival (OS) in rodent models. Asciminib is an FDA approved for the treatment of chronic myeloid leukemia and is well tolerated, likely due to its specificity for ABL1 and ABL2. Asciminib is a P-glycoprotein (P-gp) substrate and thus may be susceptible to being pumped out of tumor cells and brain endothelial cells. It is unclear if asciminib can enter the central nervous system (CNS) and brain tumors in adequate concentration to have anti-tumor effects.
Eligibility
- Age range
- 6–25 years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: * Ages 6-25 years old, inclusive. * Radiographic evidence of a recurrent/progressive brain tumor. * Tumor must be predominantly in an intraparenchymal location. * Deemed operable (able to be resected or have an open or stereotactic needle biopsy) by treating neurosurgeon. * Karnofsky/Lansky Performance Status of ≥ 60. Patients who are unable to walk because of paralysis but who are up in a wheelchair will be considered ambulatory for the purposes of the performance score. * Bone Marrow: * ANC (Absolute neutrophil count) ≥ 1000/µl (unsupported). * Platelets ≥ 100,000/µ…
Interventions
- DrugAsciminib
Commercially available stock
- DrugSildenafil
Commercially available stock
- ProcedureSurgical resection or biopsy
Standard of care
Location
- Washington University School of Medicine/St. Louis Children's HospitalSt Louis, Missouri